VPHIF (Valeo Pharma) Total Debt per Share: $0.52 (As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VPHIF Valeo Pharma Inc VPHIF
12 GF Score
Price $0.00
View Full Analysis

What is Valeo Pharma Total Debt per Share?

Valeo Pharma VPHIF -99.00% 12 Total Debt per Share is $0.52 as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

$0.52 (As of Jul. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Valeo Pharma's Total Debt Per Share for the quarter that ended in Jul. 2024 was $0.52.

Valeo Pharma Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma Total Debt per Share Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Total Debt per Share
Get a 7-Day Free Trial 0.01 0.04 0.08 0.55 0.48

Valeo Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.48 0.50 0.50 0.52
VPHIF
12GF Score
Valeo Pharma Inc VPHIF
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valeo Pharma Total Debt per Share Calculation

Valeo Pharma's Total Debt Per Share for the fiscal year that ended in Oct. 2023 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(44.12+3.41)/98.63
=0.48

Valeo Pharma's Total Debt Per Share for the quarter that ended in Jul. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(17.82+33.29)/98.68
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.52 mean?
Valeo Pharma (VPHIF) has a Total Debt per Share of $0.52 as of Jul. 2024. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Valeo Pharma and its competitors.
Is Valeo Pharma's Total Debt per Share too high?
Valeo Pharma's current Total Debt per Share is $0.52. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Valeo Pharma's Total Debt per Share compare to ZTS?
Valeo Pharma's Total Debt per Share of $0.52 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Valeo Pharma and its competitors. Valeo Pharma's current Total Debt per Share is $0.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valeo Pharma stock overvalued right now?
Valeo Pharma (VPHIF) has a current Total Debt per Share of $0.52. The current Total Debt per Share is $0.52. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current Total Debt per Share is $0.52 as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
12GF Score

Get the complete analysis for VPHIF

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price